{
  "slug": "tesamorelin",
  "name": "Tesamorelin",
  "aliases": ["Egrifta", "TH9507"],
  "category_tags": ["metabolic", "growth", "weight"],
  "typical_route": ["subQ"],
  "overview": "A synthetic growth hormone-releasing hormone (GHRH) analog that has been FDA-approved for reducing excess abdominal fat in HIV patients with lipodystrophy. It stimulates the pituitary gland to produce and release growth hormone.",
  "what_people_seek": ["reduction in visceral adipose tissue", "body composition improvement", "metabolic health support"],
  "evidence_level": "Strong",
  "risk_level": "Moderate",
  "side_effects_common": ["injection site reactions", "joint pain", "muscle pain", "peripheral edema", "carpal tunnel symptoms"],
  "who_should_avoid": ["pregnancy or breastfeeding", "active malignancy or history of cancer", "critical illness or post-surgery recovery", "diabetic retinopathy", "hypersensitivity to tesamorelin or mannitol"],
  "interactions_notes": "May affect glucose metabolism and insulin sensitivity. Discuss with clinician if taking diabetes medications, corticosteroids, or other hormonal therapies.",
  "dosing_ranges_literature": "FDA-approved dosing for lipodystrophy is 2 mg once daily via subcutaneous injection. Clinical studies have primarily used this standardized dose.",
  "reconstitution": {
    "vial_total_mg": 2,
    "common_diluents_ml": [2.2],
    "example_doses_mg": [2]
  },
  "storage_notes": "Store unreconstituted vials refrigerated at 2-8°C (36-46°F). After reconstitution, use immediately or store refrigerated for up to 3 hours. Protect from light.",
  "references": [
    {
      "id": "ref1",
      "title": "Tesamorelin for HIV-associated lipodystrophy",
      "source": "PubMed",
      "year": 2010,
      "url": "https://pubmed.ncbi.nlm.nih.gov/",
      "note": "Clinical trial data supporting FDA approval for visceral adipose tissue reduction."
    },
    {
      "id": "ref2",
      "title": "Effects of tesamorelin on body composition",
      "source": "Review",
      "year": 2013,
      "url": "https://pubmed.ncbi.nlm.nih.gov/",
      "note": "Review of tesamorelin's effects on abdominal fat and metabolic parameters."
    }
  ],
  "last_reviewed": "2025-11-03"
}
